Compare CLST & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLST | ANVS |
|---|---|---|
| Founded | 1922 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.9M | 69.1M |
| IPO Year | 2021 | 2019 |
| Metric | CLST | ANVS |
|---|---|---|
| Price | $15.95 | $1.90 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.50 |
| AVG Volume (30 Days) | 5.8K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 171.79 | 39.39 |
| EPS | ★ 0.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $106.73 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.02 | $1.54 |
| 52 Week High | $18.16 | $5.50 |
| Indicator | CLST | ANVS |
|---|---|---|
| Relative Strength Index (RSI) | 47.10 | 44.61 |
| Support Level | $15.90 | $1.79 |
| Resistance Level | $15.99 | $2.38 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 62.46 | 22.83 |
Catalyst Bancorp Inc is a bank holding company. Through its subsidiary, which is a federally chartered community-oriented savings bank, it is engaged in attracting deposits from the general public and using those funds to invest in loans and securities. The sources of funds are customer deposits, repayments of loans, maturities of investments, and funds borrowed from outside sources, which are used for the origination of loans. It derives income principally from interest earned on loans and investment securities and, to a lesser extent, from fees received in connection with the origination of loans, service charges on deposit accounts, and other services.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.